List of Jounce Therapeutics, Inc. patents

List of Jounce Therapeutics, Inc. patents

List of Tumbleweed Communications patents

List of Agfa-Gevaert patents

List of Lexar Media patents

List of funding rounds for Dataminr

Companies in the Baby food industry

Patents where

Current Assignee

Name

is

‌

Jounce Therapeutics, Inc.

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11292840 Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist	Patent 11292840 was granted and assigned to Jounce Therapeutics, Inc. on April, 2022 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	11292840	April 5, 2022
	‌ US Patent 10968277 Gene signatures for determining ICOS expression	Patent 10968277 was granted and assigned to Jounce Therapeutics, Inc. on April, 2021 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	10968277	April 6, 2021
	‌ US Patent 11384147 Anti-PD-1 antibodies and uses thereof		‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	11384147	July 12, 2022
	‌ US Patent 11359019 Antibodies to LILRB2	Patent 11359019 was granted and assigned to Jounce Therapeutics, Inc. on June, 2022 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	11359019	June 14, 2022
	‌ US Patent 10023635 Antibodies to ICOS	Patent 10023635 was granted and assigned to Jounce Therapeutics, Inc. on July, 2018 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	10023635	July 17, 2018
	‌ US Patent 10570203 Antibodies to ICOS	Patent 10570203 was granted and assigned to Jounce Therapeutics, Inc. on February, 2020 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	10570203	February 25, 2020
	‌ US Patent 10723798 Antibodies to LILRB2	Patent 10723798 was granted and assigned to Jounce Therapeutics, Inc. on July, 2020 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	10723798	July 28, 2020
	‌ US Patent 10654929 Antibodies to PD-1 and uses thereof		‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	10654929	May 19, 2020
	‌ US Patent 10618961 Antibodies to LILRB2	Patent 10618961 was granted and assigned to Jounce Therapeutics, Inc. on April, 2020 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	10618961	April 14, 2020
	‌ US Patent 10626176 Methods of treating conditions with antibodies that bind B7-H4	Patent 10626176 was granted and assigned to Jounce Therapeutics, Inc. on April, 2020 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	10626176	April 21, 2020
	‌ US Patent 11905329 Anti-PD-1 antibodies and uses thereof	Patent 11905329 was granted and assigned to Jounce Therapeutics, Inc. on February, 2024 by the United States Patent and Trademark Office.	‌ Jounce Therapeutics, Inc.	‌ Jounce Therapeutics, Inc.		United States Patent and Trademark Office	11905329	February 20, 2024

11 results

0 selected

11 results

0 selected